V

Veritas In Silico
130A

Last Price

Financial Snapshot

gainify

Market Data

Market Cap
¥3.11B
EV
¥1.21B
Shares Outstanding
6.49M
Beta
-
Industry
-

Wall Street View

Analyst Rating
-
Analyst Target Price
-
Number of Analysts
0
P/E E
-
P/Revenue E
-

Historical 3Y Growth Rate

Revenue
-
EPS
-
Operating Cash Flow
-
Free Cash Flow
-

Forecasted 3Y Growth Rate

Revenue
-
EPS
-
Operating Cash Flow
-
Free Cash Flow
-

Margins & Returns

Gross Margin E
-
Net Profit Margin E
-
ROE E
-
ROCE
-

Dividends

DPS E
-
Payout Ratio E
-
Div. Yield E
-
DPS Last 3Y CAGR
-

Price Dynamic

Price

%

1M

3M

6M

1Y

3Y

5Y

Peers

gainify

About Veritas In Silico Inc.

gainify

V

Veritas In Silico Inc.

130A

Veritas In Silico Inc. engages in the business of small molecule drug discovery and nucleic acid drug discovery targeting mRNA. The company has strategic partnership with Liverpool ChiroChem for the mRNA-targeted drug discovery and development. Veritas In Silico Inc. ...

Sector

Industry

CEO

Nakamura, Shingo

Employees

IPO Date

Headquarters

1-11-1 Nishigotanda, Shinagawa, Tokyo, 141-0031, Japan

📊 Stock Price & Performance

Review the recent 130A stock performance trends:Past 3 Months: The stock has -24.31%. Last updated: January 1, 2026 at 12:14 AM Eastern Time

💰 Financial Metrics & Reports

The current Veritas In Silico (130A) market capitalization is approximately ¥3.11B, based on its latest share price and shares outstanding. Market capitalization represents the total market value of a company's equity and is calculated by multiplying the current stock price by the number of shares outstanding. As a result, Veritas In Silico's market cap fluctuates with changes in its share price and share count. Last updated: January 1, 2026 at 12:14 AM Eastern Time

📅 Earnings & Dividends

Veritas In Silico (130A) does not currently pay a dividend. Over the last twelve months (LTM), the company paid ¥0.00 per share in dividends, and no dividend payments are currently expected over the next twelve months (NTM). Companies that do not pay dividends typically prioritize reinvesting cash into growth initiatives, capital expenditures, debt reduction, or strategic investments, though dividend policy may change in the future.

📈 Analyst Information

Based on the latest available analyst coverage, Veritas In Silico (130A) currently carries a not available consensus rating. Analyst views are forward-looking estimates and should not be considered investment advice.

Like other publicly traded stocks, Veritas In Silico (130A) shares are bought and sold on stock exchanges such as TSE and other supported markets, depending on the listing. The most common way to buy shares is through an online brokerage account. To get started, you typically need to: Open an account with a licensed stock brokerComplete the broker's verification processFund your accountPlace a buy order for Veritas In Silico (130A) shares Trading involves risk, and investors should consider their financial objectives and risk tolerance before investing.

ℹ️ Company Information

At the top right of this page, you'll see a star icon labeled Add to watchlist. Click it to add 130A to your watchlist.

Veritas In Silico trades under the ticker symbol 130A on the TSE stock exchange. The ticker 130A is used to identify the company's common stock across trading platforms, market data providers, and regulatory filings.

gainifypowered-by-sp
Socials
Send us an emailFollow us on XConnect with us on LinkedInFollow us on InstagramFollow us on ThreadsCheck us out on TrustpilotFollow us on YouTubeFind us on Google Maps

Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2026, S&P Global Market Intelligence. All rights reserved.

View Data Providers

NEWSLETTER

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.

© 2026 Gainify. All rights reserved.